Findings

What do systematic reviews say?

5 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Days missed from work or school · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

1 finding from 1 review

Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 409 participants
Very low

ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

3 findings from 1 review

Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 3799 participants
Very low
Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
18 studies · 4183 participants
Very low
Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1005 participants
Very low

Serious adverse events Median · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

1 finding from 1 review

Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
1.43 [0.85, 2.43]
14 studies · 4078 participants
Very low

Quality of life, self‐rated at post‐treatment · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

1 finding from 1 review

Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1888 participants
Very low

Proportion of participants experiencing adverse events · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

1 finding from 1 review

Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
1.27 [1.19, 1.37]
14 studies · 4214 participants
Very low